![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, July 30, 2004 8:41:04 PM
Secondly, you said:
On the other hand, a side benefit of the effort to create a classifier also renders other information. Information that can, if discovered early in the development process, actually influence the eventual drug. Perhaps making it more 'universal' in scope or conversely, more finely targeted to a specific trait or population group. While this is a beneficial outcome to the patients and the industry, it does not necessarily have a viable business application. It is obvious that while such a service would be beneficial to a drug manufacturer, if there is no associated classifier there will be no revenue stream for DNAP.
I would point out that in order to market a drug that is "finely targeted" to a specific trait or population group, you will absolutely need the classifier to identify the patient (target) from amongst the general population. In fact, the classifier would have to be a part of the FDA submission for approval to market the drug.
Later,
W2P
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM